Antonio Díaz-López

Antonio Díaz-López

Auto-generated profile, based on publicly available information

Antonio Díaz-López

Departament of Biochemistry, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), IdiPAZ, Madrid, Spain

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Cancer Management and Research
Verified
Journal Article
Open access
ACAmparo Cano
Amparo Cano
ADAntonio Diaz-Lopez
Antonio Diaz-Lopez
GMGema Moreno-Bueno
Gema Moreno-Bueno
The microRNAs (miRNAs) are a class of small, 20–22 nucleotides in length, endogenously expressed noncoding RNAs that regulate multiple targets posttranscriptionally. Interestingly, miRNAs have emerged as regulators of most physiological and pathological processes, including metastatic tumor progression, in part by controlling a reversible process called epithelial-to-mesenchymal transition (EMT). The activation of EMT increases the migratory and invasive properties fundamental for tumor cell spread while activation of the reverse mesenchymal-to-epithelial transition is required for metastasis outgrowth. The EMT triggering leads to the activation of a core of transcription factors (EMT-TFs) – SNAIL1/SNAIL2, bHLH (E47, E2-2, and TWIST1/TWIST2), and ZEB1/ZEB2 – that act as E-cadherin repressors and, ultimately, coordinate EMT. Recent evidence indicates that several miRNAs regulate the expression of EMT-TFs or EMT-activating signaling pathways. Interestingly, some miRNAs and EMT-TFs form tightly interconnected negative feedback loops that control epithelial cell plasticity, providing self-reinforcing signals and robustness to maintain the epithelial or mesenchymal cell status. Among the most significant feedback loops, we focus on the ZEB/miR-200 and the SNAIL1/miR-34 networks that hold a clear impact in the regulation of the epithelial-mesenchymal state. Recent insights into the p53 modulation of the EMT-TF/miRNA loops and epigenetic regulatory mechanisms in the context of metastasis dissemination will also be discussed. Understanding the regulation of EMT by miRNAs opens new avenues for the diagnosis and prognosis of tumors and identifies potential therapeutic targets that might help to negatively impact on metastasis dissemination and increasing patient survival.

27 September 2014 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
LALorena Alonso-Alconada
Lorena Alonso-Alconada
LMLaura Muinelo
Laura Muinelo
KMKadri Madissoo
Kadri Madissoo
ADAntonio Diaz-Lopez
Antonio Diaz-Lopez
CKCamilla Krakstad
Camilla Krakstad
MPMiguel Abal Posada
Miguel Abal Posada
About 20% of patients diagnosed with endometrial cancer (EC) are considered high-risk with unfavorable prognosis. In the framework of the European Network for Individualized Treatment in EC (ENITEC), we investigated the presence and phenotypic features of Circulating Tumor Cells (CTC) in high-risk EC patients. CTC isolation was carried out in peripheral blood samples from 34 patients, ranging from Grade 3 Stage IB to Stage IV carcinomas and recurrences, and 27 healthy controls using two methodologies. Samples were subjected to EpCAM-based immunoisolation using the CELLection™ Epithelial Enrich kit (Invitrogen, Dynal) followed by RTqPCR analysis. The phenotypic determinants of endometrial CTC in terms of pathogenesis, hormone receptor pathways, stem cell markers and epithelial to mesenchymal transition (EMT) drivers were asked. Kruskal-Wallis analysis followed by Dunn’s post-test was used for comparisons between groups. Statistical significance was set at p < 0.05. EpCAM-based immunoisolation positively detected CTC in high-risk endometrial cancer patients. CTC characterization indicated a remarkable plasticity phenotype defined by the expression of the EMT markers ETV5, NOTCH1, SNAI1, TGFB1, ZEB1 and ZEB2. In addition, the expression of ALDH and CD44 pointed to an association with stemness, while the expression of CTNNB1, STS, GDF15, RELA, RUNX1, BRAF and PIK3CA suggested potential therapeutic targets. We further recapitulated the EMT phenotype found in endometrial CTC through the up-regulation of ETV5 in an EC cell line, and validated in an animal model of systemic dissemination the propensity of these CTC in the accomplishment of metastasis. Our results associate the presence of CTC with high-risk EC. Gene-expression profiling characterized a CTC-plasticity phenotype with stemness and EMT features. We finally recapitulated this CTC-phenotype by over-expressing ETV5 in the EC cell line Hec1A and demonstrated an advantage in the promotion of metastasis in an in vivo mouse model of CTC dissemination and homing.

30 December 2005 in Cancer
Verified
Journal Article
Closed access
PDF file
CGCristina Garcia‐Aranda
Cristina Garcia‐Aranda
CJCarmen de Juan
Carmen de Juan
ADAntonio Diaz‐Lopez
Antonio Diaz‐Lopez
ASAndres Sanchez‐Pernaute
Andres Sanchez‐Pernaute
ATAntonio‐Jose Torres
Antonio‐Jose Torres
PIPilar Iniesta
Pilar Iniesta

3 October 2013 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
JDJuan Diaz-Martin
Juan Diaz-Martin
ADAntonio Díaz‐López
Antonio Díaz‐López
GMGema Moreno-Bueno
Gema Moreno-Bueno
MCM Ángeles Castilla
M Ángeles Castilla
JRJuan M Rosa‐Rosa
Juan M Rosa‐Rosa
JPJosé Palacios
José Palacios

1 September 2014 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
ADAntonio Díaz‐López
Antonio Díaz‐López
JDJuan Diaz-Martin
Juan Diaz-Martin
GMGema Moreno-Bueno
Gema Moreno-Bueno
ECEva P Cuevas
Eva P Cuevas
VSVanesa Santos
Vanesa Santos
ACAmparo Cano
Amparo Cano
Cell plasticity is emerging as a key regulator of tumor progression and metastasis. During carcinoma dissemination epithelial cells undergo epithelial to mesenchymal transition (EMT) processes characterized by the acquisition of migratory/invasive properties, while the reverse, mesenchymal to epithelial transition (MET) process, is also essential for metastasis outgrowth. Different transcription factors, called EMT‐TFs, including Snail, bHLH and Zeb families are drivers of the EMT branch of epithelial plasticity, and can be post‐transcriptionally downregulated by several miRNAs, as the miR‐200 family. The specific or redundant role of different EMT‐TFs and their functional interrelations are not fully understood. To study the interplay between different EMT‐TFs, comprehensive gain and loss‐of‐function studies of Snail1, Snail2 and/or Zeb1 factors were performed in the prototypical MDCK cell model system. We here describe that Snail1 and Zeb1 are mutually required for EMT induction while continuous Snail1 and Snail2 expression, but not Zeb1, is needed for maintenance of the mesenchymal phenotype in MDCK cells. In this model system, EMT is coordinated by Snail1 and Zeb1 through transcriptional and epigenetic downregulation of the miR‐200 family. Interestingly, Snail1 is involved in epigenetic CpG DNA methylation of the miR‐200 loci, essential to maintain the mesenchymal phenotype. The present results thus define a novel functional interplay between Snail and Zeb EMT‐TFs in miR‐200 family regulation providing a molecular link to their previous involvement in the generation of EMT process in vivo.

18 April 2014 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
JBJorge Barbazán
Jorge Barbazán
LMLaura Muinelo‐Romay
Laura Muinelo‐Romay
MVMaría Vieito
María Vieito
SCSonia Candamio
Sonia Candamio
ADAntonio Díaz‐López
Antonio Díaz‐López
RLRafael López‐López
Rafael López‐López
Circulating tumor cells (CTCs), proposed as major players in cancer dissemination, have demonstrated clinical prognostic significance in several cancer types. However, their predictive value remains unclear. Here we evaluated the clinical utility of six CTC markers (tissue specific and epithelial to mesenchymal transition transcripts) both as prognostic and predictive tools in metastatic colorectal cancer (mCRC) patients. CTCs were immunoisolated from blood in 50 mCRC patients at baseline and at 4 and 16 weeks after treatment onset. Expression levels of GAPDH, VIL1, CLU, TIMP1, LOXL3 and ZEB2 were determined by qualitative polymerase chain reaction and normalized to the unspecific cell isolation marker CD45. At baseline, median progression‐free survival (PFS) and overall survival (OS) for patients with high CTC markers were 6.3 and 12.7 months, respectively, versus 12.7 and 24.2 for patients with low CTC markers (PFS; p = 0.0003; OS; p = 0.044). Concerning response to therapy, PFS and OS for patients with increased CTC markers along treatment were, respectively, 6.6 and 13.1 months, compared with 12.7 and 24.3 for patients presenting CTC markers reduction (PFS; p = 0.004; OS; p = 0.007). Of note, CTC markers identified therapy‐refractory patients not detected by standard image techniques. Patients with increased CTC markers along treatment, but classified as responders by computed tomography, showed significantly shorter survival times (PFS: 7.8 vs. 13.2; OS: 14.4 vs. 24.4; months). In conclusion, we have generated a CTC marker panel for prognosis evaluation and the identification of patients benefiting or not from therapy in mCRC. Our methodology efficiently classified patients earlier than routine computed tomography and from a minimally invasive liquid biopsy.